Hyderabad: Hyderabad-based Bharat Biotech has announced that the animal study results of its COVID-19 vaccine -'COVAXIN' has shown positive results and has protective efficacy in a live viral challenge model.
The company took to Twitter and said, "Bharat Biotech proudly announces the animal study results of COVAXIN™ - These results demonstrate the protective efficacy in a live viral challenge model."
Earlier on September 5, the vaccine maker received the approval from Central Drugs Standard Control Organisation under the Directorate General of Health Services to conduct the phase II trials of indigenous vaccine candidate Covaxin.
Also Read: First part of phase-1 of Covaxin human trial completed at PGI Rohtak
Phase I clinical trials of the vaccine began on July 15 at 12 centres across the country where healthy volunteers were administered two doses of vaccination shots with a gap of 14 days. These trials on 375 volunteers are still continuing.
Bharat Biotech had announced on June 29 that it had successfully developed Covaxin in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
READ: Telangana to get priority in Bharat Biotech's Covid vaccine supply: KCR
